Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

The purpose of this study is to evaluate the benefit of panitumumab in addition to best supportive care compared to best supportive care alone in subjects with chemorefractory wild-type KRAS metastatic colorectal cancer.


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefractory Wild-type KRAS Metastatic Colorectal Cancer
Enrollment: 377
Study Start Date: September 2011
Estimated Study Completion Date: June 2016
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)

Arms:
- Experimental: Pmab + BSC
- Best Supportive Care Alone